The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 29, 2022

Filed:

Jan. 25, 2007
Applicants:

John P. Geibel, Branford, CT (US);

Philipp Kirchhoff, Attendorn, DE;

Inventors:

John P. Geibel, Branford, CT (US);

Philipp Kirchhoff, Attendorn, DE;

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/315 (2006.01); A61K 33/30 (2006.01); A61K 31/7048 (2006.01); A61K 31/43 (2006.01); A61K 31/65 (2006.01); A61K 31/4168 (2006.01);
U.S. Cl.
CPC ...
A61K 31/315 (2013.01); A61K 31/4168 (2013.01); A61K 31/43 (2013.01); A61K 31/65 (2013.01); A61K 31/7048 (2013.01); A61K 33/30 (2013.01);
Abstract

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.


Find Patent Forward Citations

Loading…